Please login to the form below

Not currently logged in
Email:
Password:

rivaroxaban

This page shows the latest rivaroxaban news and features for those working in and with pharma, biotech and healthcare.

Bad news for Portola as CHMP considers Factor Xa drugs

Bad news for Portola as CHMP considers Factor Xa drugs

Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa (edoxaban) - have thus far not been approved.

Latest news

  • Joerg Moeller to head Bayer R&D after operational shake-up Joerg Moeller to head Bayer R&D after operational shake-up

    It will also highlight its plans to expand the use of novel oral anticoagulant (NOAC) Xarelto (rivaroxaban) into coronary and peripheral artery disease, along with new-generation anticoagulants in mid-phase

  • J&J files would-be prostate cancer blockbuster in US J&J files would-be prostate cancer blockbuster in US

    That view was echoed by Jefferies Jeffrey Holford, who says J&J’s so-called TIRADE products - Tremfya (guselkumab) for psoriasis, cancer drug Imbruvica (ibrutinib), anticoagulant rivaroxaban (Xarelto), apalutamide, Darzalex (daratumumab)

  • Xarelto no better than aspirin in secondary stroke study Xarelto no better than aspirin in secondary stroke study

    While bleeding rates were low overall, an increase in bleeding was observed in the rivaroxaban arm compared to the low dose aspirin arm, according to the two companies. ... We are committed to continuing the extensive investigation of rivaroxaban for

  • EMA clears Bayer's Stivarga for liver cancer EMA clears Bayer's Stivarga for liver cancer

    Stivarga is a key component among a new generation of pharma products - along with cancer drug Xofigo (radium-223 dichloride), anticoagulant Xarelto (rivaroxaban), ophthalmic therapy Eylea (aflibercept) and pulmonary arterial hypertension

  • Biosimilars eat into J&J's Remicade sales Biosimilars eat into J&J's Remicade sales

    Overall J&J's group sales rose almost 2% to $18.9bn in the second quarter, with novel oral anticoagulant (NOAC) Xarelto (rivaroxaban) rising 8% to $642m in the quarter and

More from news
Approximately 14 fully matching, plus 122 partially matching documents found.

Latest Intelligence

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    Rivaroxaban. Rivaroxaban (Xarelto; Bayer and Johnson &Johnson) is an oral, once-daily, selective factor Xa inhibitor that is approved in the EU and US for the prevention of stroke and systemic ... In addition, rivaroxaban significantly reduced

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...

Infographics